Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Chemother. Pharmacol.

Title: Cancer chemotherapy and pharmacology

Publisher: Springer Nature

ISSN (Electronic): 1432-0843

ISSN (Print): 0344-5704

Publication date (Electronic): May 2016

Volume: 77

Issue: 5

Affiliations

[1 ] Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

[2 ] Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. khotta@okayama-u.ac.jp.

[3 ] Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikatacho, Kitaku, Okayama, 700-8558, Japan. khotta@okayama-u.ac.jp.

[4 ] Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.

[5 ] Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, Matsuyama, Japan.

[6 ] Department of Respiratory Medicine, NHO Iwakuni Medical Center, Iwakuni, Japan.

[7 ] Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.

[8 ] Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan.

[9 ] Department of Respiratory Medicine, NHO Fukuyama Medical Center, Fukuyama, Japan.

[10 ] Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, Japan.

[11 ] Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.

[12 ] Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikatacho, Kitaku, Okayama, 700-8558, Japan.

Article

Publisher Item ID: 10.1007/s00280-015-2910-9

DOI: 10.1007/s00280-015-2910-9

PubMed ID: 27029623

SO-VID: 5a059052-32c5-4e06-89f5-a44af4cff0dc

History

Keywords: Afatinib,Lung cancer,Response,Skin rash

Data availability:

Keywords: Afatinib, Lung cancer, Response, Skin rash

Comments

Comment on this article

scite_

Cited by 7

See all cited by